Join us for the first in our new Analytical Connections series: Drug Development & Target Interactions, exploring how advanced LC-MS/MS and MS imaging are transforming early-stage drug discovery.

Understanding the fate and effect of a candidate pharmaceutical on a biological system is a key part of the drug discovery and development process. DMPK and biomarker studies provide information on ADME, generation of potentially toxic metabolites, and dysregulation of metabolic processes, forming an essential part of the drug development package. Despite these studies, candidate drugs are often eliminated in preclinical and early clinical phases due to toxicity or undesirable DMPK properties. The combination of microsampling and the exquisite sensitivity of modern LC/MS/MS and MS imaging has the potential to rapidly produce significantly more information from early discovery samples, improving the candidate selection process. This presentation will illustrate the use of discovery and targeted LC-MS/MS as well as MS imaging to investigate the relationship between drug-metabolite exposure and changes in endogenous metabolite-lipid levels in two in vivo studies, a TKI inhibitor and an antihistamine hepatotoxin.

This event is open to all King’s staff and students; however, registration is required to attend. Please register using the link provided on this page to secure your place.

This event is part of Analytical Bites @ the Analytical Core Facilities, a platform for King’s analytical community designed to share knowledge and explore cutting-edge analytical topics & technology. We invite expert speakers from academia, core facilities, and industry with sessions that include seminars, interactive discussions, workshops and complimentary meal.